What changed: Advanced melanoma (unresectable stage III and stage IV)
Every dated change on the records linked to Advanced melanoma (unresectable stage III and stage IV), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
August 2026 · 1
2026 · 3
- 2026ApprovalVusolimogene oderparepvecVusolimogene oderparepvec approved in US
Unresectable/metastatic melanoma after anti-PD-1, with nivolumab (accelerated)
- 2026Trial resultFianlimab + cemiplimab phase 3 (first-line melanoma)Fianlimab + cemiplimab phase 3 (first-line melanoma) reported
Primary PFS endpoint not met; numerical +5.
- 2026MilestoneVusolimogene oderparepvecRP1 with nivolumab approved for PD-1-refractory melanoma
A milestone in how this cancer is treated.
2025 · 1
February 2024 · 1
2024 · 2
March 2022 · 1
2022 · 3
- 2022ApprovalRelatlimab + nivolumabRelatlimab + nivolumab approved in US
Unresectable or metastatic melanoma, age ≥12
- 2022Trial resultRELATIVITY-047RELATIVITY-047 reported
PFS HR 0.
- 2022MilestoneRELATIVITY-047RELATIVITY-047: nivolumab plus relatlimab approved; Dutch trial shows TIL beats ipilimumab
A milestone in how this cancer is treated.
2021 · 2
2018 · 3
- 2018Trial resultCheckMate 204CheckMate 204 reported
Intracranial clinical benefit 57% and complete response 26% in the asymptomatic cohort.
- 2018Trial resultCOLUMBUSCOLUMBUS reported
PFS 14.
- 2018MilestoneCheckMate 204CheckMate 204: immunotherapy doublet works in the brain
A milestone in how this cancer is treated.
October 2015 · 1
2015 · 4
- 2015ApprovalTalimogene laherparepvecTalimogene laherparepvec approved in US
Unresectable melanoma with injectable lesions
- 2015Trial resultCheckMate 067CheckMate 067 reported
10-year OS 43% vs 37% vs 19%.
- 2015Trial resultKEYNOTE-006KEYNOTE-006 reported
10-year OS 34.
- 2015MilestoneCheckMate 067CheckMate 067: nivolumab plus ipilimumab; T-VEC first oncolytic virus
A milestone in how this cancer is treated.
December 2014 · 1
September 2014 · 1
2014 · 4
- 2014ApprovalDabrafenib + trametinibDabrafenib + trametinib approved in US
BRAF V600E/K unresectable or metastatic melanoma, combination (accelerated; each drug alone approved 2013)
- 2014Trial resultcoBRIMcoBRIM reported
Median progression-free survival 12.
- 2014Trial resultCOMBI-dCOMBI-d reported
Median progression-free survival 11.
- 2014MilestonePembrolizumabPembrolizumab and nivolumab approved; KEYNOTE-006 shows PD-1 beats CTLA-4 blockade
A milestone in how this cancer is treated.